212 Pb TCMC trastuzumab

Drug Profile

212 Pb TCMC trastuzumab

Alternative Names: 212 Pb-trastuzumab

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AREVA Med
  • Developer AREVA Med; University of Alabama at Birmingham; University of Cincinnati
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer metastases; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer-metastases in USA (Intraperitoneal, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Injection)
  • 01 Jul 2016 Areva completes a phase-I clinical trial in Cancer metastases in USA (Intraperitoneal) (NCT01384253)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top